HRP20100455T1 - Maleatne soli derivata kinazolina korisne kao antiangiogeno sredstvo - Google Patents
Maleatne soli derivata kinazolina korisne kao antiangiogeno sredstvo Download PDFInfo
- Publication number
- HRP20100455T1 HRP20100455T1 HR20100455T HRP20100455T HRP20100455T1 HR P20100455 T1 HRP20100455 T1 HR P20100455T1 HR 20100455 T HR20100455 T HR 20100455T HR P20100455 T HRP20100455 T HR P20100455T HR P20100455 T1 HRP20100455 T1 HR P20100455T1
- Authority
- HR
- Croatia
- Prior art keywords
- indol
- propoxy
- oxy
- fluoro
- methoxy
- Prior art date
Links
- 150000002688 maleic acid derivatives Chemical class 0.000 title claims abstract 13
- 239000004037 angiogenesis inhibitor Substances 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims abstract 13
- 150000003839 salts Chemical class 0.000 claims abstract 9
- 238000002441 X-ray diffraction Methods 0.000 claims abstract 3
- 239000000843 powder Substances 0.000 claims abstract 3
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 claims 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims 8
- 239000000243 solution Substances 0.000 claims 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 4
- 239000011976 maleic acid Substances 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- 238000002955 isolation Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 239000007864 aqueous solution Substances 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000008025 crystallization Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000010899 nucleation Methods 0.000 claims 1
- 230000006911 nucleation Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0330002.7A GB0330002D0 (en) | 2003-12-24 | 2003-12-24 | Quinazoline derivatives |
| PCT/GB2004/005359 WO2005061488A1 (en) | 2003-12-24 | 2004-12-18 | Maleate salts of a quinazoline derivative useful as an antiangiogenic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100455T1 true HRP20100455T1 (hr) | 2010-09-30 |
Family
ID=30776508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100455T HRP20100455T1 (hr) | 2003-12-24 | 2010-08-16 | Maleatne soli derivata kinazolina korisne kao antiangiogeno sredstvo |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US20070129387A1 (ru) |
| EP (1) | EP1699782B1 (ru) |
| JP (2) | JP5009628B2 (ru) |
| KR (1) | KR101240872B1 (ru) |
| CN (2) | CN1898232B (ru) |
| AR (2) | AR046993A1 (ru) |
| AT (1) | ATE471936T1 (ru) |
| AU (1) | AU2004303590B2 (ru) |
| BR (1) | BRPI0417958B8 (ru) |
| CA (1) | CA2548662C (ru) |
| CY (1) | CY1110730T1 (ru) |
| DE (1) | DE602004027833D1 (ru) |
| DK (1) | DK1699782T3 (ru) |
| ES (1) | ES2345776T3 (ru) |
| GB (1) | GB0330002D0 (ru) |
| HK (1) | HK1095325A1 (ru) |
| HR (1) | HRP20100455T1 (ru) |
| IL (1) | IL176308A (ru) |
| MX (1) | MXPA06007191A (ru) |
| MY (1) | MY145143A (ru) |
| NO (1) | NO336613B1 (ru) |
| NZ (1) | NZ547547A (ru) |
| PL (1) | PL1699782T3 (ru) |
| PT (1) | PT1699782E (ru) |
| RS (1) | RS51387B (ru) |
| RU (1) | RU2425043C2 (ru) |
| SA (1) | SA05250464B1 (ru) |
| SI (1) | SI1699782T1 (ru) |
| TW (1) | TWI339119B (ru) |
| UA (1) | UA91332C2 (ru) |
| UY (1) | UY28702A1 (ru) |
| WO (1) | WO2005061488A1 (ru) |
| ZA (1) | ZA200605225B (ru) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| UA81619C2 (ru) * | 2002-02-01 | 2008-01-25 | Астразенека Аб | Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе |
| GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| CA2558346A1 (en) * | 2004-03-23 | 2005-10-06 | Astrazeneca Ab | Combination therapy |
| GB0523810D0 (en) * | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
| KR20080077678A (ko) * | 2005-12-22 | 2008-08-25 | 아스트라제네카 아베 | Ａｚｄ2171 및 페메트렉시드의 조합물 |
| US7851623B2 (en) | 2006-11-02 | 2010-12-14 | Astrazeneca Ab | Chemical process |
| CL2008000070A1 (es) * | 2007-01-17 | 2008-07-25 | Lg Life Sciences Ltd | Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h |
| WO2010072348A1 (en) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Biomarkers for inhibitors with anti-angiogenic activity |
| EP2481738A1 (en) * | 2009-09-25 | 2012-08-01 | Kyorin Pharmaceutical Co., Ltd. | Maleic acid salt and crystal thereof |
| US20150165028A1 (en) * | 2012-06-25 | 2015-06-18 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing cediranib |
| US9007866B2 (en) | 2013-04-23 | 2015-04-14 | Tessera Inc. | Retention optimized memory device using predictive data inversion |
| AU2014341966B2 (en) * | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CN106061261B (zh) | 2013-11-01 | 2018-04-24 | 卡拉制药公司 | 治疗化合物的结晶形式及其用途 |
| CN105461698A (zh) * | 2014-09-12 | 2016-04-06 | 杭州普晒医药科技有限公司 | 西地尼布盐及其晶型、以及其制备方法和药物组合物 |
| WO2017035170A1 (en) * | 2015-08-24 | 2017-03-02 | Pliva Hrvatska D.O.O | Solid state forms of cediranib maleate |
| HUE058114T2 (hu) | 2016-02-15 | 2022-07-28 | Astrazeneca Ab | Cediranib rögzített idõszakos adagolását tartalmazó eljárások |
| AU2017324716B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
| US10255725B2 (en) * | 2016-11-16 | 2019-04-09 | Disney Enterprises, Inc. | Augmented reality interactive experience |
| CN110817898B (zh) * | 2018-08-13 | 2021-09-03 | 中国科学院大连化学物理研究所 | 一种具有ats骨架结构的磷酸硅铝分子筛及其制备方法和应用 |
| WO2024003241A1 (en) | 2022-06-30 | 2024-01-04 | Astrazeneca Ab | Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| US5411963A (en) * | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5714493A (en) * | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US6645969B1 (en) * | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU658646B2 (en) * | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| CA2091204C (en) | 1992-03-11 | 1997-04-08 | Ronald J. Mattson | Antiischemic-piperazinyl and piperidinyl-cyclohexanes |
| GB9323290D0 (en) | 1992-12-10 | 1994-01-05 | Zeneca Ltd | Quinazoline derivatives |
| US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
| EP0746554A1 (en) * | 1994-02-23 | 1996-12-11 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
| AU2096895A (en) | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
| DE4436509A1 (de) * | 1994-10-13 | 1996-04-18 | Hoechst Schering Agrevo Gmbh | Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide |
| GB9505651D0 (en) | 1995-03-21 | 1995-05-10 | Agrevo Uk Ltd | AgrEvo UK Limited |
| US6046206A (en) * | 1995-06-07 | 2000-04-04 | Cell Pathways, Inc. | Method of treating a patient having a precancerous lesions with amide quinazoline derivatives |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| AU7340096A (en) | 1995-11-07 | 1997-05-29 | Kirin Beer Kabushiki Kaisha | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| DE19614718A1 (de) | 1996-04-15 | 1997-10-16 | Hoechst Schering Agrevo Gmbh | Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel |
| GB9707800D0 (en) | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
| EP0912559B1 (en) | 1996-07-13 | 2002-11-06 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| US6225318B1 (en) * | 1996-10-17 | 2001-05-01 | Pfizer Inc | 4-aminoquinazolone derivatives |
| AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ES2289791T3 (es) | 1997-08-22 | 2008-02-01 | Astrazeneca Ab | Derivados de oxindolilquinazolina como inhibidores de la angiogenesis. |
| US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| GB9721437D0 (en) | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
| US6172071B1 (en) | 1998-07-30 | 2001-01-09 | Hughes Institute | Lipid-lowering quinazoline derivative |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
| JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
| UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| EE05345B1 (et) * | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| DE60017179T2 (de) | 1999-10-19 | 2006-01-05 | Merck & Co., Inc. | Tyrosin kinaseinhibitoren |
| ES2306306T3 (es) * | 1999-11-05 | 2008-11-01 | Astrazeneca Ab | Nuevos derivados de quinazolina. |
| GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
| US20030119060A1 (en) * | 2001-08-10 | 2003-06-26 | Desrosiers Peter J. | Apparatuses and methods for creating and testing pre-formulations and systems for same |
| UA81619C2 (ru) | 2002-02-01 | 2008-01-25 | Астразенека Аб | Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе |
| GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
| GB0406446D0 (en) * | 2004-03-23 | 2004-04-28 | Astrazeneca Ab | Combination therapy |
| GB0523810D0 (en) * | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
-
2003
- 2003-12-24 GB GBGB0330002.7A patent/GB0330002D0/en not_active Ceased
-
2004
- 2004-12-18 DE DE602004027833T patent/DE602004027833D1/de active Active
- 2004-12-18 KR KR1020067014753A patent/KR101240872B1/ko active IP Right Grant
- 2004-12-18 RU RU2006126782/04A patent/RU2425043C2/ru active
- 2004-12-18 PL PL04806159T patent/PL1699782T3/pl unknown
- 2004-12-18 NZ NZ547547A patent/NZ547547A/xx unknown
- 2004-12-18 CA CA2548662A patent/CA2548662C/en active Active
- 2004-12-18 AU AU2004303590A patent/AU2004303590B2/en active Active
- 2004-12-18 CN CN2004800386656A patent/CN1898232B/zh active Active
- 2004-12-18 WO PCT/GB2004/005359 patent/WO2005061488A1/en active Application Filing
- 2004-12-18 EP EP04806159A patent/EP1699782B1/en active Active
- 2004-12-18 SI SI200431472T patent/SI1699782T1/sl unknown
- 2004-12-18 AT AT04806159T patent/ATE471936T1/de active
- 2004-12-18 ES ES04806159T patent/ES2345776T3/es active Active
- 2004-12-18 RS RSP-2010/0374A patent/RS51387B/en unknown
- 2004-12-18 JP JP2006546311A patent/JP5009628B2/ja active Active
- 2004-12-18 CN CN2011100351254A patent/CN102153543B/zh active Active
- 2004-12-18 BR BRPI0417958A patent/BRPI0417958B8/pt active IP Right Grant
- 2004-12-18 PT PT04806159T patent/PT1699782E/pt unknown
- 2004-12-18 UA UAA200608165A patent/UA91332C2/ru unknown
- 2004-12-18 DK DK04806159.2T patent/DK1699782T3/da active
- 2004-12-18 MX MXPA06007191A patent/MXPA06007191A/es active IP Right Grant
- 2004-12-18 US US10/581,279 patent/US20070129387A1/en not_active Abandoned
- 2004-12-22 AR ARP040104882A patent/AR046993A1/es not_active Application Discontinuation
- 2004-12-22 MY MYPI20045318A patent/MY145143A/en unknown
- 2004-12-23 UY UY28702A patent/UY28702A1/es not_active Application Discontinuation
- 2004-12-24 TW TW093140588A patent/TWI339119B/zh active
-
2005
- 2005-01-29 SA SA5250464A patent/SA05250464B1/ar unknown
-
2006
- 2006-06-12 NO NO20062703A patent/NO336613B1/no unknown
- 2006-06-14 IL IL176308A patent/IL176308A/en active IP Right Grant
- 2006-06-23 ZA ZA200605225A patent/ZA200605225B/en unknown
-
2007
- 2007-01-16 HK HK07100533.7A patent/HK1095325A1/xx unknown
-
2009
- 2009-12-23 US US12/646,153 patent/US8859570B2/en active Active
-
2010
- 2010-08-09 CY CY20101100738T patent/CY1110730T1/el unknown
- 2010-08-16 HR HR20100455T patent/HRP20100455T1/hr unknown
-
2011
- 2011-02-03 JP JP2011021384A patent/JP2011088936A/ja active Pending
-
2014
- 2014-09-18 US US14/489,721 patent/US9556151B2/en active Active
-
2016
- 2016-06-10 AR ARP160101750A patent/AR104979A2/es not_active Application Discontinuation
- 2016-09-13 US US15/264,527 patent/US9890140B2/en active Active
-
2017
- 2017-12-28 US US15/857,366 patent/US20180170913A1/en not_active Abandoned
-
2019
- 2019-01-04 US US16/240,587 patent/US20190375730A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100455T1 (hr) | Maleatne soli derivata kinazolina korisne kao antiangiogeno sredstvo | |
| EP2468281A1 (en) | Quinoline derivative-containing pharmaceutical composition | |
| HRP20231588T3 (hr) | Kombinacija koja sadrži stabilni kristal 4-oksokinolinskog spoja | |
| SI2648726T1 (en) | POLYCYCIC LPA1 ANTAGONIST AND ITS USE | |
| EA024980B1 (ru) | Лекарственные формы, содержащие основание прасугреля или его фармацевтически приемлемые соли присоединения кислоты, и способы их приготовления | |
| WO2008144730A3 (en) | Stable pharmaceutical formulation for a dpp-iv inhibitor | |
| Chaudhari et al. | Co-crystals: a review | |
| CN102827153B (zh) | 阿齐沙坦的晶型及其制备方法 | |
| RU2010103999A (ru) | Новый способ получения сухих фармацевтических форм, диспергируемых в воде, и фармацевтические композиции, полученные таким способом | |
| SI20581B (sl) | Nove hidratne oblike natrijevega alendronata, postopki za njihovo pridobivanje in ustrezne farmacevtske učinkovine | |
| HRP20151138T1 (hr) | Dihidroetorfini i njihovo pripremanje | |
| NZ568412A (en) | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same. | |
| EA200901146A1 (ru) | Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли | |
| DK1697326T3 (da) | Krystalform af en quinolinforbindelse og fremgangsmåde til fremstilling deraf | |
| CA2525700A1 (en) | S-(-)-amlodipine nicotinate and process for the preparation thereof | |
| WO2003043989A1 (en) | Hydrophilic (s)-amlodipine salts or their hydrates and pharmaceutical compositions | |
| CN104356038A (zh) | 维生素d2与d3的共晶及其制备方法和用途 | |
| CN102584826A (zh) | (6s)-5-甲基四氢叶酸盐晶型及其制备方法 | |
| CN104721828A (zh) | 一种改善晶体药物稳定性的药物组合物及其制备方法 | |
| EP2723322A1 (en) | Imatinib mesylate oral pharmaceutical composition and process for preparation thereof | |
| CN104356134A (zh) | 一种5-甲基四氢叶酸碱性氨基酸盐化合物的制备方法及5-甲基四氢叶酸碱性氨基酸盐化合物和应用 | |
| WO2011161689A1 (en) | Imatinib mesilate pharmaceutical tablet | |
| CN110963962A (zh) | 一种新的马来酸氯苯那敏晶体及其制备方法 | |
| AU2006306906B2 (en) | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same | |
| RU2009149675A (ru) | Стабильная лекарственная форма аморфных солей периндоприла, способ ее получения в промышленных масштабах и применение для лечения гипертонии |